| EPA0091 | Faster disease progression and increased viral replication among HIV-TB co-infected individuals via Mycobacterim tuberculosis mediated modulation of host intrinsic anti-viral factors | E-poster | HIV-associated viruses, co-infections and co-morbidities |
| EPA0092 | In vitro modelling to monitor pathogenic implications of viral co-infections | E-poster | HIV-associated viruses, co-infections and co-morbidities |
| EPA0093 | HIV infection enhances EBV replication and EBV-associated tumorigenesis in vivo | E-poster | HIV-associated viruses, co-infections and co-morbidities |
| EPA0094 | A panel of RBD-specific broadly neutralizing antibodies against SARS-CoV-2 variants | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0095 | Fc-modified HIV-1 broadly neutralizing monoclonal antibody, VRC01LS, shows enhanced biodistribution in human genital and rectal mucosal tissue compared to VRC01 | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0096 | COVID -19 vaccination uptake among adolescents and young people living with HIV in Kenya, 2021-2022 | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0097 | Comparison of immunogenicitiy and neutralizing antibody response of CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) between people living with HIV with CD4 ≤ 200/uL and CD4 >200 cells/uL | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0098 | Heterogeneity in neutralizing antibody responses following COVID-19 vaccination in Japanese people living with HIV | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0099 | No impact of HIV status on COVID-19 vaccine responses in Botswana | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| EPA0100 | Serum level of Macrophage migration Inhibitory Factor (MIF) is elevated during acute COVID-19 but not associated with severity, in donors from a biobank from Buenos Aires, Argentina | E-poster | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |